Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 1
2019 1
2020 1
2021 1
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
Milunović V, Mišura Jakobac K, Mandac Rogulj I, Martinović M, Radić-Krišto D, Ostojić Kolonić S. Milunović V, et al. Among authors: misura jakobac k. Expert Rev Hematol. 2020 Jul;13(7):771-779. doi: 10.1080/17474086.2020.1775575. Epub 2020 Jun 24. Expert Rev Hematol. 2020. PMID: 32579408 Review.
Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases.
Bašić-Kinda S, Mišura Jakobac K, Sinčić-Petričević J, Deak D, Vodanović M, Jakić-Bubalo M, Mitrović Z, Grubešić A, Dreta B, Županić Krmek D, Coha B, Radić-Krišto D, Aurer I. Bašić-Kinda S, et al. Among authors: misura jakobac k. Croat Med J. 2021 Oct 31;62(5):455-463. doi: 10.3325/cmj.2021.62.455-63. Croat Med J. 2021. PMID: 34730885 Free PMC article.
Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM).
Batinić J, Dreta B, Rinčić G, Mrdeža A, Jakobac KM, Krišto DR, Vujčić M, Piršić M, Jonjić Ž, Periša V, Sinčić Petričević J, Coha B, Holik H, Valković T, Stanić M, Krečak I, Stojanović A, Sajfert D, Bašić-Kinda S. Batinić J, et al. Among authors: jakobac km. Medicina (Kaunas). 2024 Nov 20;60(11):1905. doi: 10.3390/medicina60111905. Medicina (Kaunas). 2024. PMID: 39597090 Free PMC article.
Carfilzomib in relapsed/refractory multiple myeloma patients - real world evidence - experiences of the Croatian cooperative group for hematologic diseases (KROHEM).
Galusic D, Batinic J, Krecak I, Dreta B, Radic Kristo D, Pirsic M, Rincic G, Sincic-Petricevic J, Valkovic T, Vujcic M, Simunic M, Misura Jakobac K, Sedinic Lacko M, Brcic K, Perisa V, Petricevic F, Grohovac D, Holik H, Moric Peric M, Zekanovic I, Bernes P, Kuzat L, Romic I, Zupanic Krmek D, Basic-Kinda S. Galusic D, et al. Among authors: misura jakobac k. Cancer Treat Res Commun. 2025 Mar 24;43:100912. doi: 10.1016/j.ctarc.2025.100912. Online ahead of print. Cancer Treat Res Commun. 2025. PMID: 40147100 Free article.
Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases.
Aurer I, Jakšić O, Bašić-Kinda S, Mišura-Jakobac K, Sinčić-Petričević J, Novaković-Coha S, Galušić D, Holik H, Valković T, Županić-Krmek D, Hude-Dragičević I, Milunović V, Pejša V. Aurer I, et al. Among authors: misura jakobac k. Biomedicines. 2024 Dec 20;12(12):2902. doi: 10.3390/biomedicines12122902. Biomedicines. 2024. PMID: 39767808 Free PMC article.